About   Help   FAQ
Mammalian Phenotype Ontology Annotations
Query Results - Summary
Symbol
Name
ID 		Pten
phosphatase and tensin homolog
MGI:109583
559 phenotypes from 21 alleles in 80 genetic backgrounds
Export: Excel File
Allelic Composition
Genetic Background		 Annotated Term Reference
Amhr2tm3(cre)Bhr/Amhr2+
Ptentm1Hwu/Ptentm1Hwu
involves: 129S4/SvJae * 129S7/SvEvBrd * C57BL/6 		abnormal endometrium morphology J:170203
abnormal maternal decidual layer morphology J:170203
abnormal myometrium morphology J:170203
abnormal placenta labyrinth morphology J:170203
abnormal placenta vasculature J:170203
abnormal trophoblast layer morphology J:170203
decreased litter size J:170203
decreased uterine NK cell number J:170203
endometrium fibrosis J:170203
endometrium hyperplasia J:170203
reduced female fertility J:170203
normal reproductive system phenotype J:187754
uterus hyperplasia J:170203
Cd19tm1(cre)Cgn/Cd19+
Ptentm1Hwu/Ptentm1Hwu
involves: 129P2/OlaHsd * 129S4/SvJae 		abnormal B cell negative selection J:155314
abnormal B cell physiology J:83213
abnormal class switch recombination J:114881
abnormal plasma cell morphology J:114881
decreased IgG level J:114881
decreased spleen germinal center number J:83213
increased B cell apoptosis J:83213
increased B cell number J:83213
increased B cell proliferation J:83213, J:155314
increased B-1 B cell number J:83213
increased IgM level J:114881
increased marginal zone B cell number J:83213
Cd19tm1(cre)Cgn/Cd19tm1(cre)Cgn
Ptentm1Hwu/Ptentm1Hwu
involves: 129P2/OlaHsd * 129S4/SvJae 		normal immune system phenotype J:83213
Cnptm1(cre)Kan/Cnp+
Ptentm1Hwu/Ptentm1Hwu
B6N.129-Cnptm1(cre)Kan Ptentm1Hwu 		tomacula J:236408
Gt(ROSA)26Sortm1(cre/ERT)Nat/Gt(ROSA)26Sor+
Ptentm1Hwu/Ptentm1Hwu
involves: 129 * 129S4/SvJae * BALB/c * C57BL/6 		decreased tumor-free survival time J:130367
endometrium hyperplasia J:130367
increased gastrointestinal tumor incidence J:130367
increased incidence of tumors by chemical induction J:130367
increased prostate gland tumor incidence J:130367
increased prostate intraepithelial neoplasia incidence J:130367
increased skin squamous cell carcinoma incidence J:130367
increased T cell derived lymphoma incidence J:130367
increased tumor incidence J:130367
intestine polyps J:130367
prostate gland hyperplasia J:130367
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
Ptentm1Hwu/Ptentm1Hwu
involves: 129S4/SvJae * C57BL/6 		enlarged lymph nodes J:170965
enlarged spleen J:170965
hunched posture J:170965
increased acute lymphoblastic leukemia incidence J:170965
increased spleen weight J:170965
premature death J:170965
Hprt1tm1(Pbsn*-cre/ERT2)Jir/Y
Ptentm2Mak/Ptentm2Mak
involves: 129P2/OlaHsd * C57BL/6 		increased prostate gland adenocarcinoma incidence J:144357
increased prostate intraepithelial neoplasia incidence J:144357
Nkx3-1tm4(cre/ERT2)Mms/Nkx3-1+
Ptentm1Hwu/Ptentm1Hwu
involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6 		increased prostate gland adenocarcinoma incidence J:153425
increased prostate intraepithelial neoplasia incidence J:153425, J:191327
Pgrtm2(cre)Lyd/Pgr+
Ptentm1Hwu/Ptentm1Hwu
involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ 		abnormal uterus physiology J:162027
decreased uterus weight J:218222
endometrium hyperplasia J:162027
increased endometrial carcinoma incidence J:162027, J:218222
increased papilloma incidence J:218222
increased uterus weight J:162027, J:218222
premature death J:218222
Pgrtm2(cre)Lyd/Pgr+
Ptentm1Hwu/Ptentm1Hwu
involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6 		endometrium hyperplasia J:139053
increased endometrial carcinoma incidence J:139053
premature death J:139053
Ptenm1un/Ptenm1un
involves: C3HeB/FeJ * C57BL/6J 		cardia bifida J:98216
embryonic growth arrest J:98216
embryonic lethality during organogenesis, complete penetrance J:98216
incomplete embryo turning J:98216
Ptentm1.1Gle/Pten+
involves: 129S6/SvEvTac * Black Swiss * FVB/N 		endometrium hyperplasia J:158751
increased adrenal gland tumor incidence J:158751
increased lymphoma incidence J:158751
increased mammary gland tumor incidence J:158751
increased prostate gland tumor incidence J:158751
increased stomach tumor incidence J:158751
increased T cell derived lymphoma incidence J:158751
increased thyroid tumor incidence J:158751
Ptentm1.1Gle/Ptentm1.1Gle
involves: 129S6/SvEvTac * Black Swiss * FVB/N 		abnormal embryonic tissue morphology J:158751
abnormal gastrulation J:158751
abnormal rostral-caudal axis patterning J:158751
embryonic lethality, complete penetrance J:158751
Ptentm1.1Hwu/Pten+
involves: 129S4/SvJae * BALB/c 		abnormal brain vasculature morphology J:110567
abnormal metastatic potential J:110567
abnormal olfactory bulb morphology J:110567
abnormal tumor incidence J:110567
abnormal uterus morphology J:110567
increased hemangioma incidence J:110567
increased mammary adenocarcinoma incidence J:110567
increased prostate gland tumor incidence J:110567
lymphoid hyperplasia J:110567
Ptentm1.1Hwu/Pten+
involves: 129S4/SvJae * BALB/c * C57BL/6 		abnormal tumor incidence J:110567
Ptentm1.1Hwu/Pten+
involves: 129S4/SvJae * C57BL/6NTac 		increased lymphoma incidence J:170965
increased thyroid adenoma incidence J:170965
Ptentm1.1Hwu/Ptentm1.1Hwu
involves: 129S4/SvJae * BALB/c 		abnormal pericardium development J:110567
embryonic lethality during organogenesis, complete penetrance J:110567
open neural tube J:110567
wavy neural tube J:110567
Ptentm1.1Jaes/Ptentm1.1Jaes
B6.129S6(FVB)-Ptentm1.1Jaes 		abnormal CNS synaptic transmission J:234430
abnormal synaptic depression J:234430
Ptentm1.1Mro/Pten+
Not Specified 		increased metastatic potential J:236514
increased pheochromocytoma incidence J:236514
Ptentm1.1Mro/Ptentm1.1Mro
involves: BALB/cJ 		abnormal embryo development J:77123
embryonic lethality J:77123
increased tumor incidence J:77123
Ptentm1.1Mwst/Ptentm1.1Mwst
Tg(S100a4-cre)1Gle/0
involves: FVB/N 		increased mammary gland tumor incidence J:153747
Ptentm1.1Mwst/Ptentm1.1Mwst
Tg(TPO-cre)1Shk/0
involves: 129 * FVB/NCr 		abnormal thyroid follicular cell morphology J:225245
Ptentm1.1Yxy/Ptentm1.1Yxy
involves: C57BL/6 		abnormal cellular respiration J:308567
abnormal endocytosis J:290673
abnormal glutamate-mediated receptor currents J:256248
abnormal mitochondrial morphology J:308567
abnormal mitophagy J:308567
abnormal olfactory bulb development J:290673
abnormal olfactory bulb mitral cell layer morphology J:290673
normal behavior/neurological phenotype J:256248
normal cardiovascular system phenotype J:308567
normal cellular phenotype J:290673, J:308567
disorganized mitochondrial cristae J:308567
fast extinction of fear memory J:256248
normal growth/size/body region phenotype J:256248
impaired olfaction J:290673
impaired spatial learning J:256248
increased glutamic acid level J:290673
increased myocardial fiber mitochondrial DNA content J:308567
increased myocardial infarct size J:308567
increased susceptibility to induced morbidity/mortality J:308567
increased susceptibility to myocardial ischemic injury J:308567
normal nervous system phenotype J:256248, J:290673
reduced long-term potentiation J:256248
normal reproductive system phenotype J:256248
Ptentm1.2Mwst/Pten+
involves: 129S6/SvEvTac * Black Swiss * FVB/N 		endometrium hyperplasia J:158751
increased adrenal gland tumor incidence J:158751
increased gastrointestinal tumor incidence J:158751
increased lymphoma incidence J:158751
increased mammary adenoacanthoma incidence J:158751
increased mammary gland tumor incidence J:158751
increased prostate gland tumor incidence J:158751
increased stomach tumor incidence J:158751
increased T cell derived lymphoma incidence J:158751
increased thyroid tumor incidence J:158751
increased uterus carcinoma incidence J:158751
Ptentm1.2Mwst/Ptentm1.2Mwst
involves: 129S6/SvEvTac * Black Swiss * FVB/N 		abnormal embryonic tissue morphology J:158751
abnormal gastrulation J:158751
abnormal rostral-caudal axis patterning J:158751
embryonic lethality, complete penetrance J:158751
Ptentm1Engc/Pten+
either: (involves: 129 * CD-1) or (involves: 129 * A/J * C57BL/6J) or (involves: 129 * C57BL/6J * CD-1) 		increased brain weight J:200739
megacephaly J:200739
Ptentm1Engc/Pten+
involves: CD-1 		abnormal cell physiology J:197051
Ptentm1Engc/Ptentm1Engc
either: (involves: 129 * CD-1) or (involves: 129 * A/J * C57BL/6J) or (involves: 129 * C57BL/6J * CD-1) 		increased brain weight J:197051
megacephaly J:197051
Ptentm1Engc/Ptentm1Engc
involves: CD-1 		abnormal cerebral cortex pyramidal cell morphology J:210487
abnormal cerebral hemisphere morphology J:210487
abnormal hippocampus granule cell morphology J:210487
abnormal hippocampus pyramidal cell morphology J:210487
abnormal microglial cell physiology J:210487
abnormal social investigation J:210487
astrocytosis J:210487
decreased body size J:210487
enlarged cerebellum J:210487
impaired balance J:210487
increased astrocyte number J:210487
increased brain size J:210487
increased cell proliferation J:210487
increased oligodendrocyte number J:210487
Ptentm1Hwu/Pten+
involves: 129S4/SvJae * BALB/c 		abnormal tumor incidence J:110567
Ptentm1Hwu/Pten+
Tg(Pbsn-cre)4Prb/0
involves: 129S4/SvJae * BALB/c * C57BL/6 * DBA/2 		increased prostate intraepithelial neoplasia incidence J:93902
Ptentm1Hwu/Pten+
Tg(Nkx2-1-cre)2Sand/0
B6.Cg-Ptentm1Hwu Tg(Nkx2-1-cre)2Sand 		abnormal thyroid gland morphology J:197590
decreased thyroxine level J:197590
increased thyroid tumor incidence J:197590
Ptentm1Hwu/Pten+
Tg(Nkx2-1-cre)2Sand/0
involves: 129S4/SvJae * BALB/c * C57BL/6 		abnormal thyroid follicle morphology J:197590
enlarged thyroid gland J:197590
increased thyroxine level J:197590
thyroid gland hyperplasia J:197590
Ptentm1Hwu/Pten+
Tg(KRT14-cre)#Smr/0
involves: 129S4/SvJae * C57BL/6J * SJL/J 		increased mammary adenocarcinoma incidence J:138927
increased mammary gland tumor incidence J:138927
premature death J:138927
Ptentm1Hwu/Ptentm1Hwu
involves: 129S4/SvJae 		abnormal muscle fiber morphology J:169364
abnormal response to injury J:165283
increased prostate gland adenocarcinoma incidence J:144810
increased prostate intraepithelial neoplasia incidence J:144810
Ptentm1Hwu/Ptentm1Hwu
A1cfTg(Myh6-cre/Esr1*)1Jmk/A1cf+
involves: 129S4/SvJae * FVB/N 		abnormal response to cardiac infarction J:149180
decreased myocardial infarct size J:149180
Ptentm1Hwu/Ptentm1Hwu
Amhr2tm3(cre)Bhr/Amhr2+
involves: 129S4/SvJae * 129S7/SvEvBrd 		abnormal pregnancy J:142150
decreased litter size J:142150
increased granulosa cell tumor incidence J:142150, J:222579
increased metastatic potential J:142150
normal reproductive system phenotype J:142150
Ptentm1Hwu/Ptentm1Hwu
Cnptm1(cre)Kan/Cnp+
involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ 		abnormal brain white matter morphology J:161841
abnormal corpus callosum morphology J:161841
abnormal myelin sheath morphology J:161841
abnormal oligodendrocyte morphology J:161841
abnormal salivary gland morphology J:161841
abnormal Schwann cell morphology J:161841
abnormal sciatic nerve morphology J:161841
cataract J:161841
hypermyelination J:161841
increased brain size J:161841
megacolon J:161841
premature death J:161841
reduced fertility J:161841
Ptentm1Hwu/Ptentm1Hwu
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * 129S4/SvJae 		abnormal alveolar macrophage morphology J:148947
abnormal cytokine level J:148947
abnormal macrophage chemotaxis J:148947
abnormal neutrophil physiology J:114699, J:145331, J:148947
decreased susceptibility to bacterial infection J:148947
decreased susceptibility to bacterial infection induced morbidity/mortality J:148947
impaired neutrophil recruitment J:148947
increased susceptibility to bacterial infection J:148947
increased susceptibility to bacterial infection induced morbidity/mortality J:148947
lung inflammation J:148947
pulmonary edema J:148947
Ptentm1Hwu/Ptentm1Hwu
Scgb1a1tm1.1(cre)Fjd/Scgb1a1+
involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ 		no abnormal phenotype detected J:131721
Ptentm1Hwu/Ptentm1Hwu
Slc6a3tm1.1(cre)Bkmn/Slc6a3+
involves: 129S4/SvJae * C57BL/6 		abnormal behavioral response to xenobiotic J:153622
abnormal dopaminergic neuron morphology J:153622
abnormal midbrain morphology J:153622
abnormal nervous system physiology J:153622
abnormal striatum morphology J:153622
abnormal substantia nigra pars compacta morphology J:153622
abnormal substantia nigra pars reticulata morphology J:153622
normal behavior/neurological phenotype J:153622
increased dopamine level J:153622
neuron hypertrophy J:153622
Ptentm1Hwu/Ptentm1Hwu
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129S4/SvJae * C57BL/6 * DBA 		abnormal fatty acids level J:88441
abnormal liver morphology J:218587
decreased circulating free fatty acids level J:88441
decreased circulating glucose level J:88441
decreased circulating insulin level J:88441
decreased circulating leptin level J:88441
decreased total body fat amount J:88441
enlarged liver J:88441, J:171445
hepatic steatosis J:88441, J:160759, J:218587
impaired lipolysis J:88441
improved glucose tolerance J:88441
increased cholangiocarcinoma incidence J:218587
increased circulating alanine transaminase level J:218587
increased hepatocellular carcinoma incidence J:218587
increased hepatocyte apoptosis J:218587
increased hepatocyte proliferation J:218587
increased insulin sensitivity J:88441
increased liver glycogen level J:88441
increased liver triglyceride level J:88441, J:160759
increased liver tumor incidence J:218587
increased liver weight J:88441, J:160759
macrovesicular hepatic steatosis J:171445
oxidative stress J:218587
pale liver J:88441
Ptentm1Hwu/Ptentm1Hwu
Tg(Adipoq-cre)1Evdr/0
involves: 129S4/SvJae * C57BL/6J * FVB/NJ 		normal neoplasm J:237232
Ptentm1Hwu/Ptentm1Hwu
Tg(Alb1-cre)1Dlr/0
involves: 129S4/SvJae * FVB/N 		bile duct hyperplasia J:111718
increased cholangiocarcinoma incidence J:111718
increased hepatocellular carcinoma incidence J:111718
Ptentm1Hwu/Ptentm1Hwu
Tg(CAG-Bgeo/ALPP)1Lbe/0
Tg(Cela1-cre/ERT)1Dam/0
involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ 		normal endocrine/exocrine gland phenotype J:102226
Ptentm1Hwu/Ptentm1Hwu
Tg(Camk2a-cre)T50Stl/0
Tg(Thy1-EGFP)MJrs/0
involves: 129S4/SvJae * BALB/c * C57BL/6J * CBA 		abnormal dendrite morphology J:145970
increased brain size J:145970
Ptentm1Hwu/Ptentm1Hwu
Tg(CD2-icre)4Kio/0
involves: 129S4/SvJae * C57BL/6 * C57BL/10 * CBA/Ca 		enlarged thymus J:216983
Ptentm1Hwu/Ptentm1Hwu
Tg(Cdh5-cre)7Mlia/0
involves: 129S4/SvJae * BALB/c * C57BL/6 * FVB/N 		abnormal definitive hematopoiesis J:135172
enlarged liver J:135172
enlarged lymph nodes J:135172
enlarged spleen J:135172
enlarged thymus J:135172
increased acute lymphoblastic leukemia incidence J:135172
increased acute promyelocytic leukemia incidence J:135172
increased leukocyte cell number J:135172
increased neutrophil cell number J:135172
Ptentm1Hwu/Ptentm1Hwu
Tg(Cdh16-cre)91Igr/0
involves: 129S4/SvJae * BALB/c * C57BL/6J * ICR 		abnormal ureter morphology J:137073
abnormal urinary bladder urothelium morphology J:137073
normal renal/urinary system phenotype J:137073
Ptentm1Hwu/Ptentm1Hwu
Tg(Cdh16-cre)91Igr/0
involves: 129S4/SvJae * ICR 		abnormal endometrium morphology J:137442
abnormal epididymis epithelium morphology J:137442
abnormal reproductive system morphology J:137442
abnormal seminal vesicle morphology J:137442
abnormal vas deferens morphology J:137442
endometrium hyperplasia J:137442
normal neoplasm J:137442
Ptentm1Hwu/Ptentm1Hwu
Tg(Ckmm-cre)5Khn/?
involves: 129S4/SvJae * FVB 		decreased circulating glucose level J:169364
decreased circulating insulin level J:169364
enhanced skeletal muscle regeneration J:169364
Ptentm1Hwu/Ptentm1Hwu
Tg(Cr2-cre)3Cgn/0
involves: 129S4/SvJae 		preweaning lethality, complete penetrance J:157297
Ptentm1Hwu/Ptentm1Hwu
Tg(CYP19A1-cre)1Jri/0
involves: 129S4/SvJae 		abnormal luteolysis J:138315
abnormal ovarian follicle morphology J:138315
decreased granulosa cell apoptosis J:138315
enhanced female fertility J:138315
enlarged ovary J:138315
impaired luteal cell differentiation J:138315
increased corpora lutea number J:138315
increased granulosa cell proliferation J:138315
increased superovulation rate J:138315
normal neoplasm J:138315
Ptentm1Hwu/Ptentm1Hwu
Tg(Ddx4-cre)1Dcas/0
involves: 129S4/SvJae * FVB/N 		abnormal ovary physiology J:138697
enlarged ovary J:138697
reduced female fertility J:138697
Ptentm1Hwu/Ptentm1Hwu
Tg(Ddx4-cre/ERT2)1Dcas/0
involves: 129S4/SvJae * FVB/N 		abnormal primordial ovarian follicle morphology J:138697
enlarged ovary J:138697
Ptentm1Hwu/Ptentm1Hwu
Tg(Fabp1-cre)1Jig/0
involves: 129S4/SvJae * FVB/N 		abnormal renal/urinary system morphology J:106662
abnormal urinary bladder urothelium morphology J:106662
abnormal urination J:106662
hydronephrosis J:106662
increased carcinoma incidence J:106662
increased colon adenocarcinoma incidence J:106662
increased metastatic potential J:106662
increased prostate gland tumor incidence J:106662
increased renal carcinoma incidence J:106662
increased squamous cell carcinoma incidence J:106662
increased urethra carcinoma incidence J:106662
increased urinary bladder carcinoma incidence J:106662
premature death J:106662
prostate gland anterior lobe hyperplasia J:106662
Ptentm1Hwu/Ptentm1Hwu
Tg(Fabp4-cre)1Abel/0
involves: 129S4/SvJae 		normal adipose tissue phenotype J:97588
decreased circulating insulin level J:97588
decreased circulating resistin level J:97588
improved glucose tolerance J:97588
increased insulin sensitivity J:97588
Ptentm1Hwu/Ptentm1Hwu
Tg(Gdf9-icre)5092Coo/0
B6.Cg-Ptentm1Hwu Tg(Gdf9-icre)5092Coo 		abnormal corpus luteum morphology J:131827
abnormal estrous cycle J:131827
abnormal oocyte morphology J:131827
abnormal ovarian follicle morphology J:131827
abnormal ovarian folliculogenesis J:131827
abnormal primordial ovarian follicle morphology J:131827
absent primordial ovarian follicles J:131827
decreased primordial ovarian follicle number J:131827
enlarged ovary J:131827
female infertility J:131827
increased follicle stimulating hormone level J:131827
increased luteinizing hormone level J:131827
premature ovarian failure J:131827
Ptentm1Hwu/Ptentm1Hwu
Tg(Gdf9-icre)5092Coo/0
involves: 129S4/SvJae * C57BL/6 		abnormal primordial ovarian follicle morphology J:151696
Ptentm1Hwu/Ptentm1Hwu
Tg(Gdf9-icre)5092Coo/?
involves: 129S4/SvJae * C57BL/6J 		abnormal primordial ovarian follicle morphology J:155357
Ptentm1Hwu/Ptentm1Hwu
Tg(GFAP-cre)25Mes/0
involves: 129S4/SvJae * FVB/N 		abnormal Bergmann glial cell differentiation J:100428
abnormal Bergmann glial cell morphology J:100428
abnormal cerebellar foliation J:100428
abnormal cerebellar granule cell morphology J:100428
abnormal cerebellar granule layer morphology J:100428
abnormal cerebellar Purkinje cell layer J:100428
abnormal cerebellum development J:100428
ectopic Bergmann glia cells J:100428
ectopic Purkinje cell J:100428
enlarged cerebellum J:100428
increased brain size J:100428
lethality at weaning, complete penetrance J:100428
megacephaly J:100428
Ptentm1Hwu/Ptentm1Hwu
Tg(Gfap-cre)77.6Mvs/0
involves: 129S4/SvJae * BALB/c * C57BL/6NHsd 		abnormal neuron differentiation J:146630
abnormal neuronal precursor proliferation J:146630
abnormal olfaction J:146630
abnormal olfactory bulb morphology J:146630
abnormal postnatal subventricular zone morphology J:146630
abnormal response to CNS ischemic injury J:146630
abnormal response to novel odor J:146630
increased neuronal precursor cell number J:146630
normal neoplasm J:146630, J:154673
Ptentm1Hwu/Ptentm1Hwu
Tg(GZMB-cre)1Jcb/0
involves: 129S4/SvJae * FVB/N 		abnormal CD8-positive, alpha-beta T cell physiology J:164425
decreased interleukin-2 secretion J:164425
Ptentm1Hwu/Ptentm1Hwu
Tg(Ins2-cre)25Mgn/0
involves: 129S4/SvJae * BALB/c * C57BL/6 * DBA 		abnormal pancreatic beta cell morphology J:170129
increased pancreatic beta cell mass J:170129
postnatal growth retardation J:170129
Ptentm1Hwu/Ptentm1Hwu
Tg(Ins2-cre)25Mgn/0
involves: 129S4/SvJae * C57BL/6 * DBA 		abnormal pancreas physiology J:106937
abnormal pancreatic beta cell morphology J:170206
decreased cellular sensitivity to oxidative stress J:106937
decreased susceptibility to injury J:106937
enlarged pancreatic islets J:106937
normal homeostasis/metabolism phenotype J:170206
hypoglycemia J:106937
improved glucose tolerance J:170206
increased body weight J:170206
increased insulin secretion J:170206
increased insulin sensitivity J:170206
increased pancreatic beta cell mass J:170206
increased pancreatic beta cell number J:106937
increased pancreatic beta cell proliferation J:106937
increased pancreatic islet number J:106937
Ptentm1Hwu/Ptentm1Hwu
Tg(KRT14-cre)#Smr/0
FVB.Cg-Ptentm1Hwu Tg(KRT14-cre)#Smr 		abnormal epidermal layer morphology J:199362
hyperkeratosis J:199362
increased skin hamartoma incidence J:199362
increased skin papilloma incidence J:199362
skin lesions J:199362
thick epidermis J:199362
thick epidermis suprabasal layer J:199362
thick skin J:199362
Ptentm1Hwu/Ptentm1Hwu
Tg(KRT14-cre)#Smr/0
involves: 129S4/SvJae * C57BL/6J * SJL/J 		abnormal hair shaft morphology J:138927
abnormal nipple morphology J:138927
abnormal vibrissa follicle morphology J:138927
acanthosis J:138927
decreased survivor rate J:138927
enlarged hair follicles J:138927
enlarged thyroid gland J:138927
flaky skin J:138927
hyperkeratosis J:138927
increased mammary adenocarcinoma incidence J:138927
increased mammary gland tumor incidence J:138927
increased skin papilloma incidence J:138927
increased skin tumor incidence J:138927
increased thyroid tumor incidence J:138927
postnatal lethality, incomplete penetrance J:138927
premature death J:138927
skin lesions J:138927
wrinkled skin J:138927
Ptentm1Hwu/Ptentm1Hwu
Tg(MMTV-cre)4Mam/0
involves: 129S4/SvJae * FVB 		abnormal branching of the mammary ductal tree J:78415
mammary gland duct hyperplasia J:78415
Ptentm1Hwu/Ptentm1Hwu
Tg(MMTV-cre)7Mul/0
involves: 129S4/SvJae * FVB/N 		normal neoplasm J:133305
Ptentm1Hwu/Ptentm1Hwu
Tg(MMTV-cre)#Tfln/0
involves: 129S4/SvJae 		abnormal branching of the mammary ductal tree J:78415
abnormal involution of the mammary gland J:78415
abnormal mammary gland epithelium morphology J:78415
abnormal mammary gland growth during pregnancy J:78415
abnormal mammary gland lobule morphology J:78415
increased fibroadenoma incidence J:78415
increased mammary adenocarcinoma incidence J:78415
increased mammary gland tumor incidence J:78415
mammary gland duct hyperplasia J:78415
mammary gland hyperplasia J:78415
Ptentm1Hwu/Ptentm1Hwu
Tg(Mx1-cre)1Cgn/0
B6.Cg-Tg(Mx1-cre)1Cgn Ptentm1Hwu 		abnormal liver size J:232645
anemia J:232645
decreased B cell number J:232645
decreased lymphocyte cell number J:232645
decreased T cell number J:232645
enlarged spleen J:232645
increased granulocyte number J:232645
increased liver weight J:232645
increased macrophage cell number J:232645
increased monocyte cell number J:232645
increased spleen weight J:232645
increased T cell acute lymphoblastic leukemia incidence J:232645
increased tumor incidence J:232645
premature death J:232645
thrombocytosis J:232645
Ptentm1Hwu/Ptentm1Hwu
Tg(Mx1-cre)1Cgn/0
BKS.Cg-Ptprcb Thy1a Tg(Mx1-cre)1Cgn Ptentm1Hwu 		abnormal blood cell morphology/development J:109085
abnormal hematopoietic stem cell physiology J:109085
decreased bone marrow cell number J:109085
enlarged thymus J:109085
extramedullary hematopoiesis J:109085
increased acute lymphoblastic leukemia incidence J:109085
increased acute promyelocytic leukemia incidence J:109085
increased leukemia incidence J:109085
premature death J:109085
spleen hyperplasia J:109085
Ptentm1Hwu/Ptentm1Hwu
Tg(Mx1-cre)1Cgn/0
involves: 129S4/SvJae * C57BL/6 * C57BL/6J * CBA 		abnormal platelet activation J:165893
decreased bleeding time J:165893
increased platelet aggregation J:165893
thrombocytosis J:165893
Ptentm1Hwu/Ptentm1Hwu
Tg(Mx1-cre)1Cgn/0
involves: 129S4/SvJae * C57BL/6 * CBA 		enlarged spleen J:169097
enlarged thymus J:169097
increased acute lymphoblastic leukemia incidence J:169097
intestine polyps J:118329
premature death J:169097
Ptentm1Hwu/Ptentm1Hwu
Tg(Nes-cre)1Atp/0
involves: 129S4/SvJae * FVB/N 		abnormal brain morphology J:73255
abnormal brainstem morphology J:73255
abnormal cerebellum morphology J:73255
abnormal cortical ventricular zone morphology J:73255
abnormal hippocampus layer morphology J:73255
absent cerebellar foliation J:73255
eyelids open at birth J:73255
increased brain size J:73255
increased brain weight J:73255
increased neuronal precursor cell number J:73255
megacephaly J:73255
neonatal lethality, complete penetrance J:73255
Ptentm1Hwu/Ptentm1Hwu
Tg(Nkx2-1-cre)2Sand/0
B6.Cg-Ptentm1Hwu Tg(Nkx2-1-cre)2Sand 		abnormal thyroid follicle morphology J:197590
abnormal thyroid gland morphology J:197590
decreased thyroxine level J:197590
enlarged thyroid gland J:197590
increased thyroid adenoma incidence J:197590
increased thyroid-stimulating hormone level J:197590
postnatal lethality, complete penetrance J:197590
thyroid gland hyperplasia J:197590
Ptentm1Hwu/Ptentm1Hwu
Tg(Nkx2-1-cre)2Sand/0
involves: 129S4/SvJae * BALB/c * C57BL/6 		abnormal lung development J:167962
abnormal lung morphology J:167962
abnormal thyroid gland morphology J:197590
decreased susceptibility to injury J:167962
enlarged thyroid gland J:197590
normal homeostasis/metabolism phenotype J:197590
increased club cell number J:167962
increased lung endothelial cell proliferation J:167962
normal mortality/aging J:197590
pulmonary hyperplasia J:167962
thyroid gland hyperplasia J:197590
Ptentm1Hwu/Ptentm1Hwu
Tg(Nkx2-1-cre)2Sand/0
involves: 129S4/SvJae * C57BL/6 		increased club cell number J:157922
Ptentm1Hwu/Ptentm1Hwu
Tg(Pbsn-cre)4Prb/0
involves: 129 * 129S4/SvJae * C57BL/6 * DBA/2 		female infertility J:142106
increased prostate gland adenocarcinoma incidence J:142106
increased prostate gland tumor incidence J:142106
increased prostate intraepithelial neoplasia incidence J:138565
Ptentm1Hwu/Ptentm1Hwu
Tg(Pbsn-cre)4Prb/0
involves: 129S4/SvJae * BALB/c * C57BL/6 * DBA/2 		abnormal prostate gland epithelium morphology J:93902
abnormal prostate gland morphology J:124208
abnormal prostate gland physiology J:93902, J:124208
abnormal renal/urinary system physiology J:124208
decreased tumor incidence J:124208
decreased tumor-free survival time J:124208
enlarged prostate gland J:93902
increased prostate gland adenocarcinoma incidence J:93902, J:124208
increased prostate gland tumor incidence J:124208
increased prostate gland weight J:124208
increased prostate intraepithelial neoplasia incidence J:93902, J:106650
premature death J:93902
prostate gland epithelial hyperplasia J:93902
prostate gland hyperplasia J:93902
prostate gland inflammation J:93902
pyelonephritis J:124208
Ptentm1Hwu/Ptentm1Hwu
Tg(Pbsn-cre)4Prb/0
involves: 129S4/SvJae * C57BL/6 * DBA/2 		enlarged prostate gland anterior lobe J:170965
increased carcinoma incidence J:268934
increased metastatic potential J:268934
increased prostate gland adenocarcinoma incidence J:184935, J:212219, J:268934
increased prostate gland tumor incidence J:170965, J:172730, J:268934
increased prostate gland weight J:170965
increased prostate intraepithelial neoplasia incidence J:131932, J:212219, J:268934
normal mortality/aging J:212219
prostate gland hyperplasia J:170965
Ptentm1Hwu/Ptentm1Hwu
Tg(Pbsn-cre)20Fwan/?
involves: 129S4/SvJae * C57BL/6 * FVB/NCrl 		increased prostate gland adenocarcinoma incidence J:238768
increased prostate intraepithelial neoplasia incidence J:238768
Ptentm1Hwu/Ptentm1Hwu
Tg(Pdx1-cre)89.1Dam/0
involves: 129S4/SvJae * C57BL/6 * CBA 		abnormal centroacinar cell of Langerhans morphology J:102226
abnormal exocrine pancreas morphology J:102226
abnormal pancreatic acinar cell morphology J:102226
abnormal pancreatic acinus morphology J:102226
enlarged pancreatic islets J:102226
normal homeostasis/metabolism phenotype J:102226
increased malignant tumor incidence J:102226
increased pancreatic acinar cell number J:102226
increased pancreatic ductal adenocarcinoma incidence J:102226
increased pancreatic intraepithelial neoplasia incidence J:102226
pancreatic islet hyperplasia J:102226
premature death J:102226
Ptentm1Hwu/Ptentm1Hwu
Tg(Pdx1-cre/Esr1*)35.10Dam/0
involves: 129S4/SvJae * C57BL/6 * CBA 		pancreatic islet hyperplasia J:102226
Ptentm1Hwu/Ptentm1Hwu
Tg(Pgc-cre,-secNluc)#Hcz/0
involves: 129S4/SvJae 		increased mammary adenocarcinoma incidence J:338079
Ptentm1Hwu/Ptentm1Hwu
Tg(Plp1-cre/ERT2)1Ueli/0
involves: 129S4/SvJae * C57BL/6 * DBA/2 		abnormal brain white matter morphology J:161841
abnormal corpus callosum morphology J:161841
abnormal myelin sheath morphology J:161841
abnormal optic nerve morphology J:161841
hypermyelination J:161841
Ptentm1Hwu/Ptentm1Hwu
Tg(Scgb1a1-cre)1Tauc/0
involves: 129S4/SvJae * C57BL/6 		normal respiratory system phenotype J:136369
Ptentm1Hwu/Ptentm1Hwu
Tg(SFTPC-rtTA)5Jaw/0
Tg(tetO-cre)1Jaw/0
involves: 129 * 129S4/SvJae * C57BL/6 * FVB/N 		abnormal lung epithelium morphology J:146355
abnormal respiratory epithelium morphology J:146355
bronchial epithelial hyperplasia J:146355
bronchiolar epithelial hyperplasia J:146355
increased club cell number J:146355
increased solitary pulmonary neuroendocrine cell number J:146355
normal neoplasm J:146355
Ptentm1Hwu/Ptentm1Hwu
Tg(TPO-cre)1Shk/0
involves: 129S4/SvJae * FVB/NCr 		enlarged thyroid gland J:177181
Ptentm1Hwu/Ptentm1Hwu
Tg(Tyr-cre)1Lru/0
B6.Cg-Ptentm1Hwu Tg(Tyr-cre)1Lru 		abnormal digestion J:155110
abnormal enteric ganglia morphology J:155110
abnormal enteric nervous system morphology J:155110
abnormal enteric neuron morphology J:155110
abnormal intestine morphology J:155110
distended cecum J:155110
hyperpigmentation J:155110
postnatal lethality, complete penetrance J:155110
slow postnatal weight gain J:155110
Ptentm1Hwu/Ptentm1Hwu
Tg(Vil1-cre)997Gum/0
involves: 129S4/SvJae * BALB/c * C57BL/6J * SJL 		abnormal duodenum morphology J:150553
abnormal intestinal enteroendocrine cell morphology J:150553
abnormal intestinal goblet cell morphology J:150553
abnormal intestinal mucosa morphology J:150553
abnormal intestine morphology J:150553
abnormal jejunum morphology J:150553
abnormal Paneth cell morphology J:150553
abnormal small intestinal crypt cell proliferation J:150553
abnormal small intestinal villus morphology J:150553
abnormal small intestine crypts of Lieberkuhn morphology J:150553
abnormal small intestine morphology J:150553
branched small intestinal villi J:150553
Ptentm1Hwu/Ptentm1Hwu
Tg(Zp3-cre)93Knw/0
B6.Cg-Ptentm1Hwu Tg(Zp3-cre)93Knw 		normal reproductive system phenotype J:151696
Ptentm1Hwu/Ptentm1Hwu
Twist2tm1.1(cre)Dor/Twist2+
B6.129-Twist2tm1.1(cre)Dor Ptentm1Hwu 		abnormal lung development J:192736
abnormal lung morphology J:192736
abnormal lung vasculature morphology J:192736
abnormal lung-associated mesenchyme development J:192736
abnormal vascular development J:192736
cyanosis J:192736
decreased blood oxygen capacity J:192736
hemorrhage J:192736
lethality throughout fetal growth and development, incomplete penetrance J:192736
neonatal lethality, complete penetrance J:192736
respiratory distress J:192736
Ptentm1Mak/Pten+
B6.129P2-Ptentm1Mak 		abnormal embryonic tissue morphology J:93530
abnormal placenta morphology J:93530
decreased embryo size J:93530
embryonic lethality during organogenesis, incomplete penetrance J:93530
enlarged allantois J:93530
failure of chorioallantoic fusion J:93530
failure of initiation of embryo turning J:93530
increased adrenal gland tumor incidence J:93530
increased endometrial carcinoma incidence J:93530
increased lymphoma incidence J:93530
increased tumor incidence J:93530
kinked neural tube J:93530
open neural tube J:93530
Ptentm1Mak/Pten+
involves: 129P2/OlaHsd * C57BL/6J 		abnormal seminiferous tubule morphology J:50437
colon polyps J:50437
endometrium hyperplasia J:63478
enlarged Peyer's patches J:63478
increased adrenal gland tumor incidence J:63478
increased carcinoma incidence J:50437
increased endometrial carcinoma incidence J:63478
increased fibroadenoma incidence J:63478
increased hamartoma incidence J:63478
increased incidence of tumors by ionizing radiation induction J:50437
increased leukemia incidence J:50437
increased lymphoma incidence J:63478
increased mammary adenocarcinoma incidence J:63478
increased mammary gland tumor incidence J:63478
increased prostate gland tumor incidence J:63478
increased T cell derived lymphoma incidence J:50437
increased tumor incidence J:50437
Ptentm1Mak/Ptentm1Mak
involves: 129P2/OlaHsd * C57BL/6J 		abnormal allantois morphology J:50437
abnormal brain development J:50437
abnormal developmental patterning J:50437
abnormal somite development J:50437
disorganized embryonic tissue J:50437
embryonic growth retardation J:50437
embryonic lethality during organogenesis, complete penetrance J:50437
failure of chorioallantoic fusion J:50437
Ptentm1Mro/Pten+
Tg(Pbsn-cre)4Prb/0
involves: C57BL/6 * DBA/2 		increased prostate intraepithelial neoplasia incidence J:184533
Ptentm1Mro/Pten+
Tg(KLK3-cre)D4Trp/0
involves: 129P2/OlaHsd * FVB 		abnormal prostate gland epithelium morphology J:99524
increased prostate gland adenocarcinoma incidence J:99524
increased prostate gland tumor incidence J:99524
increased prostate gland weight J:99524
increased prostate intraepithelial neoplasia incidence J:99524
prostate gland hyperplasia J:99524
Ptentm1Mro/Ptentm1Mro
Tg(En2-cre)22Alj/0
Not Specified 		abnormal cerebellar molecular layer J:77123
abnormal cerebellum development J:77123
abnormal cerebellum external granule cell layer morphology J:77123
abnormal cerebellum morphology J:77123
abnormal cerebellum vermis morphology J:77123
absent cerebellar foliation J:77123
ataxia J:77123
decreased locomotor activity J:77123
ectopic Purkinje cell J:77123
enlarged cerebellum J:77123
impaired balance J:77123
impaired neuronal migration J:77123
normal neoplasm J:77123
Purkinje cell degeneration J:77123
Ptentm1Mro/Ptentm1Mro
Tg(KLK3-cre)D4Trp/0
involves: 129P2/OlaHsd * FVB 		prostate gland epithelial hyperplasia J:99524
Ptentm1Mro/Ptentm1Mro
Tg(Pcp2-cre)756Mro/0
involves: FVB/N 		abnormal cerebellar Purkinje cell layer J:77123
abnormal Purkinje cell dendrite morphology J:77123
abnormal Purkinje cell morphology J:77123
Purkinje cell degeneration J:77123
Ptentm1Ppp/Pten+
involves: 129S1/Sv * C57BL/6J 		increased malignant tumor incidence J:49532
Ptentm1Ppp/Ptentm1Ppp
involves: 129S1/Sv * C57BL/6J 		embryonic lethality between implantation and somite formation, complete penetrance J:49532
Ptentm1Ppp/Ptentm2Ppp
involves: 129S1/Sv * C57BL/6 		abnormal prostate gland morphology J:86212
increased prostate gland tumor incidence J:86212
prenatal lethality, incomplete penetrance J:86212
prostate gland anterior lobe hyperplasia J:86212
prostate gland dorsolateral lobe hyperplasia J:86212
prostate gland epithelial hyperplasia J:86212
Ptentm1Rdp/Ptentm1Rdp
Tg(Tyr-cre/ERT2)13Bos/0
involves: 129S6/SvEvTac * C57BL/6 * FVB/N 		normal pigmentation phenotype J:151023
Ptentm1Rps/Pten+
B6.129S1-Ptentm1Rps 		abnormal social investigation J:144937
decreased prepulse inhibition J:144937
increased brain weight J:144937
megacephaly J:144937
Ptentm1Rps/Pten+
B6.129S1-Ptentm1Rps/Nci 		abnormal behavior J:235927
abnormal social investigation J:235927
decreased aggression towards male mice J:235927
increased stereotypic behavior J:235927
Ptentm1Rps/Pten+
involves: 129S1/Sv * 129S1/SvImJ * C57BL/6J 		abnormal prostate gland epithelium morphology J:75085
increased prostate intraepithelial neoplasia incidence J:75085
Ptentm1Rps/Pten+
involves: 129S1/Sv * C57BL/6J 		abnormal lymph node B cell domain morphology J:53065
abnormal thyroid gland morphology J:53065
endometrium hyperplasia J:53065
enlarged spleen J:53065
enlarged thymus J:53065
increased leukemia incidence J:53065
increased liver adenoma incidence J:53065
increased lymphoma incidence J:53065
increased prostate intraepithelial neoplasia incidence J:53065
increased teratoma incidence J:53065
increased thyroid carcinoma incidence J:53065
increased tumor incidence J:53065
intestine polyps J:53065
lymph node hyperplasia J:53065
premature death J:53065
Ptentm1Rps/Ptentm1Rps
involves: 129S1/Sv * C57BL/6J 		disorganized embryonic tissue J:53065
embryonic lethality between implantation and somite formation, complete penetrance J:53065
Ptentm2.1Gle/Pten+
involves: 129S6/SvEvTac * Black Swiss * FVB/N 		abnormal thyroid follicular cell morphology J:158751
endometrium hyperplasia J:158751
increased adrenal gland tumor incidence J:158751
increased lymphoma incidence J:158751
increased mammary adenoacanthoma incidence J:158751
increased mammary gland tumor incidence J:158751
increased prostate gland tumor incidence J:158751
increased T cell derived lymphoma incidence J:158751
increased thyroid tumor incidence J:158751
Ptentm2.1Gle/Ptentm2.1Gle
involves: 129S6/SvEvTac * Black Swiss * FVB/N 		abnormal embryonic tissue morphology J:158751
abnormal gastrulation J:158751
abnormal rostral-caudal axis patterning J:158751
embryonic lethality, complete penetrance J:158751
Ptentm2.1Ppp/Ptentm2.1Ppp
involves: 129S1/Sv 		abnormal dendrite morphology J:181347
abnormal excitatory postsynaptic currents J:181347
abnormal miniature excitatory postsynaptic currents J:181347
abnormal synaptic transmission J:181347
increased dendritic spine density J:181347
increased miniature excitatory postsynaptic current amplitude J:181347
increased miniature excitatory postsynaptic current frequency J:181347
Ptentm2.1Ppp/Ptentm2.1Ppp
Tg(Dhh-cre)1Mejr/0
involves: 129S1/Sv * C57BL/6 * FVB/N * SJL 		abnormal nervous system morphology J:195067
abnormal sciatic nerve morphology J:195067
abnormal trigeminal nerve morphology J:195067
increased neurofibrosarcoma incidence J:195067
premature death J:195067
Ptentm2.1Ppp/Ptentm2.1Ppp
Tg(Osr1-cre)4Mrt/0
involves: 129S1/Sv * 129X1/SvJ 		increased prostate intraepithelial neoplasia incidence J:192348
Ptentm2.1Ppp/Ptentm2.1Ppp
Tg(Pbsn-cre)4Prb/0
involves: 129S1/Sv * C57BL/6 * DBA/2 		abnormal prostate gland epithelium morphology J:86212
abnormal prostate gland morphology J:86212
enlarged prostate gland J:86212
increased prostate gland adenocarcinoma incidence J:100683, J:163589
increased prostate gland tumor incidence J:86212, J:100683
increased prostate intraepithelial neoplasia incidence J:100683, J:163589, J:200002, J:239660
prostate gland epithelial hyperplasia J:86212, J:100683
prostate gland hyperplasia J:86212
Ptentm2.1Ppp/Ptentm2.1Ppp
Tg(Pbsn-cre)8113ANg/0
involves: 129S1/Sv * C57BL/6 		abnormal prostate gland morphology J:86212
enlarged prostate gland J:86212
increased prostate gland tumor incidence J:86212
prostate gland epithelial hyperplasia J:86212
Ptentm2.1Ppp/Ptentm2.1Ppp
Tg(TPO-cre)1Shk/0
129S1.Cg-Ptentm2.1Ppp Tg(TPO-cre)1Shk 		decreased thyroid-stimulating hormone level J:165293
increased thyroid adenoma incidence J:165293
increased thyroid carcinoma incidence J:165293
increased thyroxine level J:165293
premature death J:165293
thyroid gland hyperplasia J:165293
Ptentm2.1Ppp/Ptentm2.1Ppp
Tg(Tyr-cre/ERT2)13Bos/0
involves: 129S1/Sv * FVB 		normal pigmentation phenotype J:151023
Ptentm2.1Ppp/Ptentm2.1Ppp
Tnfrsf4tm2(cre)Nik/Tnfrsf4+
involves: 129S1/Sv * 129X1/SvJ 		increased germinal center B cell number J:164283
increased IgG1 level J:164283
increased T follicular helper cell number J:164283
Ptentm2Hwu/Pten+
involves: 129S4/SvJae * BALB/c 		abnormal tumor incidence J:110567
Ptentm2Hwu/Pten+
involves: 129S4/SvJae * C57BL/6 		abnormal tumor incidence J:110567
Ptentm2Mak/Ptentm2Mak
involves: 129P2/OlaHsd 		abnormal astrocyte physiology J:176586
Ptentm2Mak/Ptentm2Mak
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129P2/OlaHsd * C57BL/6 * C57BL/6J * DBA 		abnormal cellular cholesterol metabolism J:90905
abnormal hepatocyte morphology J:90905
abnormal liver sinusoid morphology J:90905
decreased circulating insulin level J:90905
decreased fasting circulating glucose level J:90905
enlarged liver J:90905
increased circulating alanine transaminase level J:90905
increased circulating alkaline phosphatase level J:90905
increased circulating aspartate transaminase level J:90905
increased hepatocellular carcinoma incidence J:90905
increased hepatocyte number J:90905
increased hepatocyte proliferation J:90905
increased insulin sensitivity J:90905
increased liver adenoma incidence J:90905
increased liver triglyceride level J:90905
increased liver weight J:90905
increased metastatic potential J:90905
increased saturated fatty acids level J:90905
Mallory bodies J:90905
microvesicular hepatic steatosis J:90905
oxidative stress J:90905
pale liver J:90905
Ptentm2Mak/Ptentm2Mak
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129P2/OlaHsd * C57BL/6 * DBA 		abnormal hepatocyte morphology J:138099
abnormal hepatocyte physiology J:220381
abnormal liver morphology J:138099
enlarged liver J:138099
hepatic steatosis J:138099
increased circulating alanine transaminase level J:138099
increased circulating alkaline phosphatase level J:138099
increased hepatocellular carcinoma incidence J:138099
increased hepatocyte proliferation J:138099
increased liver adenoma incidence J:138099
increased liver cholesterol level J:138099
increased liver triglyceride level J:138099
liver fibrosis J:138099
liver inflammation J:138099
Mallory bodies J:138099
pale liver J:138099
Ptentm2Mak/Ptentm2Mak
Tg(Ckmm-cre)5Khn/0
involves: 129P2/OlaHsd * FVB 		abnormal heart left ventricle morphology J:79151
abnormal heart morphology J:79151
cardiac hypertrophy J:79151
decreased cardiac muscle contractility J:79151
enlarged heart J:79151
increased myocardial fiber size J:79151
Ptentm2Mak/Ptentm2Mak
Tg(Col2a1-cre)1Xya/?
involves: 129P2/OlaHsd 		abnormal bone marrow cavity morphology J:143447
abnormal bone structure J:143447
abnormal cartilage morphology J:143447
abnormal chondrocyte morphology J:143447
abnormal epiphyseal plate morphology J:143447
abnormal long bone epiphysis morphology J:143447
abnormal long bone hypertrophic chondrocyte zone J:143447
abnormal long bone morphology J:143447
abnormal tumor susceptibility J:143447
ectopic cartilage J:143447
hindlimb paralysis J:143447
increased body length J:143447
increased bone mineral density J:143447
kyphosis J:143447
long tail J:143447
premature death J:143447
Ptentm2Mak/Ptentm2Mak
Tg(Cyp1a1-cre)1Dwi/0
involves: 129P2/OlaHsd * C57BL/6 * CBA 		abnormal behavior J:143082
normal digestive/alimentary phenotype J:143082
endometrium hyperplasia J:143082
hepatic steatosis J:143082
increased hepatocellular carcinoma incidence J:143082
increased liver weight J:143082
increased lymphoma incidence J:143082
Ptentm2Mak/Ptentm2Mak
Tg(Cyp1a1-cre/ERT)1Dwi/0
involves: 129P2/OlaHsd * C57BL/6 * C57BL/6J * CBA 		normal renal/urinary system phenotype J:169565
Ptentm2Mak/Ptentm2Mak
Tg(Eno2-cre)39Jme/0
involves: 129P2/OlaHsd * C57BL/6 * SJL 		abnormal behavior J:109635
abnormal dendrite morphology J:109635
abnormal dentate gyrus morphology J:109635
abnormal hippocampal mossy fiber morphology J:109635
abnormal hippocampus CA1 region morphology J:109635
abnormal innervation J:109635
abnormal maternal nurturing J:109635
abnormal nest building behavior J:109635
abnormal sexual interaction J:109635
abnormal social investigation J:109635
abnormal synapse morphology J:109635
abnormal synaptic vesicle number J:109635
ectopic neuron J:109635
impaired spatial learning J:109635
increased anxiety-related response J:109635
increased brain weight J:109635
increased dendritic spine density J:109635
increased dentate gyrus size J:109635
increased locomotor activity J:109635
increased startle reflex J:109635
increased stereotypic behavior J:109635
increased thigmotaxis J:109635
megacephaly J:109635
neuron hypertrophy J:109635
reduced sensorimotor gating J:109635
sporadic seizures J:109635
thickened cerebral cortex J:109635
Ptentm2Mak/Ptentm2Mak
Tg(Fabp1-cre)1Jig/0
involves: 129P2/OlaHsd * C57BL/6 * FVB/N 		abnormal urinary bladder urothelium morphology J:113388
abnormal urothelium morphology J:113388
hydronephrosis J:113388
increased incidence of tumors by chemical induction J:113388
increased urinary bladder transitional cell carcinoma incidence J:113388
Ptentm2Mak/Ptentm2Mak
Tg(Gfap-cre)1Sbk/0
involves: 129P2/OlaHsd 		abnormal cerebellar foliation J:75500
abnormal cerebellar granule cell morphology J:75500
abnormal cerebellar molecular layer J:75500
abnormal cerebellum external granule cell layer morphology J:75500
abnormal cerebellum morphology J:75500
abnormal dentate gyrus morphology J:75500
abnormal hippocampus morphology J:75500
abnormal hippocampus pyramidal cell layer J:75500
abnormal Purkinje cell morphology J:75500
abnormal spike wave discharge J:149829
ataxia J:75500, J:149829
decreased hippocampus pyramidal cell number J:75500
decreased Purkinje cell number J:75500
gliosis J:75500
hippocampal neuron degeneration J:75500
hydrocephaly J:75500
increased brain size J:75500, J:149829
increased hamartoma incidence J:75500
lethargy J:75500
megacephaly J:75500, J:149829
neuron hypertrophy J:149829
premature death J:75500, J:149829
seizures J:75500
tonic-clonic seizures J:149829
Ptentm2Mak/Ptentm2Mak
Tg(Hoxb7-cre)5526Cmb/0
involves: 129P2/OlaHsd 		abnormal glomerular capillary morphology J:122953
abnormal kidney collecting duct morphology J:122953
abnormal renal glomerulus morphology J:122953
decreased body size J:122953
ectopic ureteric bud J:122953
impaired branching involved in ureteric bud morphogenesis J:122953
postnatal lethality, complete penetrance J:122953
Ptentm2Mak/Ptentm2Mak
Tg(KLK3-cre)13Saa/0
involves: 129P2/OlaHsd * C57BL/6 		increased metastatic potential J:214242
increased prostate gland adenocarcinoma incidence J:214242
increased prostate gland tumor incidence J:214242
increased prostate intraepithelial neoplasia incidence J:214242
premature death J:214242
Ptentm2Mak/Ptentm2Mak
Tg(KRT5-cre)1Xya/0
involves: 129P2/OlaHsd 		epidermal hyperplasia J:101602
hair follicle outer root sheath hyperplasia J:101602
Ptentm2Mak/Ptentm2Mak
Tg(MMTV-cre)#Tfln/0
involves: 129P2/OlaHsd * C57BL/6 * FVB/N 		increased mammary adenocarcinoma incidence J:224955
increased mammary gland tumor incidence J:224955
increased mammary gland tumor incidence in breeding females J:224955
increased myoepithelioma incidence J:224955
increased spindle cell carcinoma incidence J:224955
Ptentm2Mak/Ptentm2Mak
Tg(Nes-cre/ERT2,-ALPP)1Sbk/0
involves: 129P2/OlaHsd 		abnormal cerebellar granule cell morphology J:237990
abnormal cerebellar molecular layer J:237990
abnormal cerebellar Purkinje cell layer J:237990
abnormal cerebellum morphology J:237990
abnormal nervous system physiology J:237990
ataxia J:237990
ectopic cerebellar granule cells J:237990
hydrocephaly J:237990
increased brain size J:237990
lethargy J:237990
megacephaly J:237990
normal neoplasm J:237990
premature death J:237990
seizures J:237990
thin cerebellar granule layer J:237990
Ptentm2Mak/Ptentm2Mak
Tg(SFTPC-rtTA)5Jaw/0
Tg(tetO-cre)1Jaw/0
involves: 129 * 129P2/OlaHsd * C57BL/6 * C57BL/6J 		abnormal alveolocapillary membrane morphology J:127405
abnormal lung development J:127405
abnormal lung saccule morphology J:127405
abnormal pulmonary alveolus epithelial cell morphology J:127405
abnormal type I pneumocyte morphology J:127405
abnormal type II pneumocyte morphology J:127405
bronchiolar epithelial hyperplasia J:127405
cyanosis J:127405
decreased alveolar lamellar body number J:127405
decreased surfactant secretion J:127405
decreased survivor rate J:127405
hypoxia J:127405
increased bronchioalveolar stem cell number J:127405
increased incidence of tumors by chemical induction J:127405
increased lung adenocarcinoma incidence J:127405
increased lung squamous cell carcinoma incidence J:127405
increased mesenchymal cell proliferation involved in lung development J:127405
neonatal lethality, incomplete penetrance J:127405
pulmonary hyperplasia J:127405
respiratory acidosis J:127405
respiratory distress J:127405
respiratory failure J:127405
small lung saccule J:127405
Ptentm2Mak/Ptentm2Mak
Tg(Vil1-cre/ERT2)23Syr/0
involves: 129P2/OlaHsd * C57BL/6 * CBA 		normal digestive/alimentary phenotype J:143082
ruffled hair J:143082
Ptentm2Mak/Ptentm2Mak
Tg(Wap-cre)11738Mam/0
involves: 129P2/OlaHsd * C57BL/6 * FVB/N * SJL 		increased mammary adenocarcinoma incidence J:224955
increased mammary gland tumor incidence J:224955
increased mammary gland tumor incidence in breeding females J:224955
increased myoepithelioma incidence J:224955
increased spindle cell carcinoma incidence J:224955
Tg(Pten)1Srn/0
involves: C57BL/6 * CBA 		abnormal adipose tissue morphology J:182671
abnormal brown adipose tissue morphology J:182671
abnormal brown adipose tissue physiology J:182671
abnormal cell physiology J:182671
abnormal excitatory postsynaptic potential J:234430
decreased body fat mass J:182671
decreased body weight J:182671
decreased brown fat cell lipid droplet size J:182671
decreased cell proliferation J:182671
decreased circulating cholesterol level J:182671
decreased circulating insulin level J:182671
decreased circulating insulin-like growth factor I level J:182671
decreased circulating leptin level J:182671
decreased embryo size J:182671
decreased epididymal fat pad weight J:182671
decreased fasting circulating glucose level J:182671
decreased incidence of tumors by chemical induction J:182671
decreased susceptibility to diet-induced hepatic steatosis J:182671
decreased white fat cell size J:182671
enhanced coordination J:182671
extended life span J:182671
increased adipocyte glucose uptake J:182671
increased basal metabolism J:182671
increased energy expenditure J:182671
increased insulin sensitivity J:182671
polyphagia J:182671
postnatal lethality, incomplete penetrance J:182671
Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support. 		last database update
12/10/2024
MGI 6.24 		The Jackson Laboratory